BioXcel Therapeutics (BTAI) News Today → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free BTAI Stock Alerts $2.07 -0.02 (-0.96%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14, 2024 | markets.businessinsider.comHold Rating on Bioxcel Therapeutics Amid Growth Potential and Financial UncertaintiesMay 14, 2024 | americanbankingnews.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Given Consensus Rating of "Hold" by AnalystsMay 13, 2024 | marketbeat.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest UpdateBioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) was the recipient of a significant decrease in short interest in the month of April. As of April 30th, there was short interest totalling 1,500,000 shares, a decrease of 28.2% from the April 15th total of 2,090,000 shares. Based on an average trading volume of 1,440,000 shares, the short-interest ratio is currently 1.0 days.May 12, 2024 | americanbankingnews.comBioXcel Therapeutics (NASDAQ:BTAI) Stock Rating Reaffirmed by HC WainwrightMay 10, 2024 | marketbeat.comBioXcel Therapeutics (NASDAQ:BTAI) Releases Earnings Results, Misses Expectations By $0.19 EPSBioXcel Therapeutics (NASDAQ:BTAI - Get Free Report) announced its earnings results on Thursday. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.19). BioXcel Therapeutics had a negative return on equity of 890.63% and a negative net margin of 12,974.86%. The company had revenue of $0.58 million during the quarter, compared to the consensus estimate of $0.42 million. During the same period in the prior year, the firm posted ($1.84) earnings per share.May 10, 2024 | markets.businessinsider.comBullish Outlook: Bioxcel Therapeutics’ Revenue Surge and Promising Clinical Trials Fuel Buy RatingMay 10, 2024 | finance.yahoo.comBioXcel Therapeutics First Quarter 2024 Earnings: Misses ExpectationsMay 10, 2024 | finance.yahoo.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comQ1 2024 BioXcel Therapeutics Inc Earnings CallMay 9, 2024 | investorplace.comBTAI Stock Earnings: BioXcel Therapeutics Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | msn.comBioXcel Therapeutics GAAP EPS of -$0.87 misses by $0.12, revenue of $0.58M misses by $0.05MMay 9, 2024 | globenewswire.comBioXcel Therapeutics Reports First Quarter 2024 Financial ResultsMay 8, 2024 | msn.comBioXcel Therapeutics Q1 2024 Earnings PreviewMay 1, 2024 | msn.com2 Contracts Traded for 20JUN24 BTI PHY DN Single Stock Dividend Neutral FutureApril 29, 2024 | marketbeat.comShort Interest in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Declines By 16.1%BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) was the recipient of a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 2,090,000 shares, a decline of 16.1% from the March 31st total of 2,490,000 shares. Based on an average daily volume of 1,510,000 shares, the short-interest ratio is presently 1.4 days.April 26, 2024 | markets.businessinsider.comHold Rating on Bioxcel Therapeutics Amid Strategic and Clinical Trial UncertaintiesApril 25, 2024 | globenewswire.comBioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024April 24, 2024 | uk.investing.comBioXcel Therapeutics to launch phase 3 trial for at-home useApril 24, 2024 | globenewswire.comBioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual MeetingApril 23, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for BioXcel Therapeutics Amidst Expansion Opportunities and FDA-Approved IGALMI™April 22, 2024 | globenewswire.comBioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market PotentialApril 18, 2024 | marketbeat.comQ1 2024 EPS Estimates for BioXcel Therapeutics, Inc. Lifted by HC Wainwright (NASDAQ:BTAI)BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Free Report) - HC Wainwright boosted their Q1 2024 earnings per share estimates for shares of BioXcel Therapeutics in a report released on Monday, April 15th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.69) per shareApril 17, 2024 | investing.comBioXcel Therapeutics stock target cut, retains buy ratingApril 17, 2024 | marketbeat.comHC Wainwright Comments on BioXcel Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:BTAI)BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for BioXcel Therapeutics in a research report issued to clients and investors on Monday, April 15th. HC Wainwright analyst R. Selvaraju anticipates tApril 17, 2024 | msn.comBioXcel Therapeutics (BTAI) Price Target Decreased by 9.82% to 10.71April 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Bioxcel Therapeutics Amid Strategic Clinical Trials and Regulatory PotentialApril 13, 2024 | marketbeat.comShort Interest in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Drops By 20.7%BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 2,490,000 shares, a decrease of 20.7% from the March 15th total of 3,140,000 shares. Currently, 10.5% of the shares of the company are sold short. Based on an average trading volume of 1,490,000 shares, the short-interest ratio is currently 1.7 days.April 12, 2024 | investing.comBioXcel Therapeutics to begin phase 3 trial for Alzheimer's treatmentApril 11, 2024 | investing.comBioXcel Therapeutics CCO sells $2.6k in stockApril 10, 2024 | uk.investing.comBioXcel Therapeutics CSO sells shares worth over $2.8kApril 10, 2024 | investing.comBioxcel Therapeutics exec sells over $400 in stockApril 10, 2024 | investing.comBioXcel Therapeutics CEO sells shares worth over $13,000April 10, 2024 | finance.yahoo.comBioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s DementiaApril 10, 2024 | globenewswire.comBioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer's DementiaApril 9, 2024 | insidertrades.comInsider Selling: BioXcel Therapeutics, Inc. (NASDAQ:BTAI) CEO Sells 5,268 Shares of StockMarch 30, 2024 | marketbeat.comShort Interest in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Decreases By 20.9%BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) was the recipient of a large drop in short interest in March. As of March 15th, there was short interest totalling 3,140,000 shares, a drop of 20.9% from the February 29th total of 3,970,000 shares. Based on an average daily volume of 1,530,000 shares, the days-to-cover ratio is currently 2.1 days. Approximately 14.6% of the company's stock are short sold.March 25, 2024 | globenewswire.comBioXcel Therapeutics Announces $25 Million Registered Direct OfferingMarch 24, 2024 | finance.yahoo.comBioXcel Therapeutics Full Year 2023 Earnings: Revenues DisappointMarch 18, 2024 | marketbeat.comBioXcel Therapeutics' (BTAI) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $11.00 price target on shares of BioXcel Therapeutics in a research note on Monday.March 18, 2024 | marketbeat.comBioXcel Therapeutics (NASDAQ:BTAI) Price Target Cut to $7.00 by Analysts at Canaccord Genuity GroupCanaccord Genuity Group decreased their price target on BioXcel Therapeutics from $18.00 to $7.00 and set a "buy" rating on the stock in a research note on Thursday.March 18, 2024 | markets.businessinsider.comBuy Rating Affirmed for BioXcel Therapeutics: FDA Pathway Clear for BXCL501 ExpansionMarch 15, 2024 | au.news.yahoo.comTapeworm eggs found in brain of man with penchant for 'undercooked' baconMarch 15, 2024 | markets.businessinsider.comBioXcel Gets European Patent For Sublingual Dexmedetomidine To Treat Agitation In Dementia PatientsMarch 15, 2024 | markets.businessinsider.comBioxcel Therapeutics: Hold Rating Amid Financial and Operational UncertaintiesMarch 15, 2024 | tmcnet.comBioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual DexmedetomidineMarch 15, 2024 | finance.yahoo.comBioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual DexmedetomidineMarch 15, 2024 | globenewswire.comBioXcel Therapeutics Announces European Patent Office's Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual DexmedetomidineMarch 15, 2024 | msn.comPetco CEO Ron Coughlin steps down, ex-BestBuy exec named as replacementMarch 15, 2024 | msn.comFDA approves first drug for serious liver diseaseMarch 15, 2024 | au.lifestyle.yahoo.comApple acquires AI startup specializing in overlooking manufacturing components Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address I’m afraid WWIII is a very real possibility (Ad)As one top U.S. cyber official claims: This [tech] is “the most powerful weapon of our time.” That's also why I've produced this new film. Take a look. BTAI Media Mentions By Week BTAI Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BTAI News Sentiment▼0.340.50▲Average Medical News Sentiment BTAI News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BTAI Articles This Week▼45▲BTAI Articles Average Week Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Vaccitech News Marinus Pharmaceuticals News Barinthus Biotherapeutics News Chimerix News Spero Therapeutics News Oncolytics Biotech News Connect Biopharma News ProPhase Labs News Corvus Pharmaceuticals News Jaguar Health News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BTAI) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingA letter is coming from the "Bureau of the Fiscal Service".Stansberry ResearchElon’s New Device is About to Shock the WorldInvestorPlaceMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders Alliance[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
